Table 3.
Multivariate analysis of prognostic factors in all patients (N = 216)
| Overall survival (OS) | |||
|---|---|---|---|
| Hazard ratio | 95% CI | P-value | |
| Time of VTE occurrence (early vs. late and no VTE) | 1.897 | 1.183–3.040 | 0.008 |
| Khorana score (high-risk vs. intermediate-risk) | 0.967 | 0.622–1.504 | 0.881 |
| ECOG PS (2–3 vs 0–1) | 2.118 | 1.267–3.541 | 0.004 |
| NLR (≥2.7 vs. < 2.7) | 1.432 | 1.003–2.046 | 0.048 |
| PLR (≥180 vs. < 180) | 1.257 | 0.884–1.787 | 0.202 |
| WBC (≥11,000 /μLvs. <11,000 /μL) | 1.29 | 0.788–2.113 | 0.311 |
| Hb (< 10 g/dL vs. ≥10 g/dL) | 1.242 | 0.760–2.030 | 0.387 |
| Na (< 135 mmol/L vs. ≥135 mmol/L) | 1.61 | 1.070–2.422 | 0.022 |
| Albumin (< 3.5 g/dL vs. ≥3.5 g/dL) | 1.036 | 0.691–1.552 | 0.865 |
| CA19–9 (≥1000 U/mL vs. < 1000 U/mL) | 1.364 | 1.013–1.836 | 0.041 |
| Liver metastases (Yes vs. No) | 1.382 | 1.006–1.899 | 0.046 |
| Number of metastatic organs (≥3 vs. < 3) | 0.752 | .0521–1.086 | 0.129 |
NLR Neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, Hb hemoglobin, CA19–9 cancer antigen 19–9, WBC White blood cell